Relay Therapeutics
RLAY
165 hedge funds and large institutions have $1.9B invested in Relay Therapeutics in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 70 increasing their positions, 37 reducing their positions, and 25 closing their positions.
56,467% more call options, than puts
Call options by funds: $1.7M | Put options by funds: $3K
89% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 37
20% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 25
2% more funds holding
Funds holding: 161 → 165 (+4)
2.36% more ownership
Funds ownership: 102.77% → 105.12% (+2.4%)
31% less capital invested
Capital invested by funds: $2.76B → $1.9B (-$863M)
71% less funds holding in top 10
Funds holding in top 10: 7 → 2 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$49.7M |
| 2 |
Morgan Stanley
New York
|
+$38.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.8M |
| 4 |
BlackRock
New York
|
+$23.7M |
| 5 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$42.6M |
| 2 |
CC
Casdin Capital
New York
|
-$31.6M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$25.8M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$16.1M |
| 5 |
JP Morgan Chase
New York
|
-$10.5M |
RLAY Hedge Fund Activity: Q4 2022 in Review
165 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q4 2022, worth a combined $1.9B — down 31% from $2.76B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RLAY positions and 25 closed out — a net gain of 5 holders — while 70 added to existing stakes and 37 trimmed.
The largest buyer was State Street, adding an estimated $49.7M. The largest seller was Fidelity Investments, cutting an estimated $42.6M.
- 165 institutional investors held Relay Therapeutics (RLAY) as of Q4 2022, up from 161 in Q3 2022.
- Funds reported $1.9B of Relay Therapeutics stock for Q4 2022, down 31% quarter-over-quarter.
- 30 funds opened new Relay Therapeutics positions in Q4 2022 and 25 closed out, a net change of +5 holders.
- The largest Relay Therapeutics buyer in Q4 2022 was State Street, an estimated $49.7M added.
- The largest Relay Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $42.6M sold.
Based on aggregated 13F filings for Q4 2022.